Holding(s) in Company

RNS Number : 4962Q

Hikma Pharmaceuticals Plc

29 February 2016

 

For filings with the FCA include the annex
For filings with issuer exclude the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii				Hikma Pharmaceuticals PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	New issued share capital affected existing holding percentage				ü
3. Full name of person(s) subject to the notification obligation: iii		Darhold Limited
4. Full name of shareholder(s)  (if different from 3.):iv		Darhold Limited
5. Date of the transaction and date on which the threshold is crossed or reached: v		29 February 2016
6. Date on which issuer notified:		29 February 2016
7. Threshold(s) that is/are crossed or reached: vi, vii		25%

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of  voting rights x

Indirect

Direct xi

Indirect xii

Direct

Indirect

GB00B0LCW083

57,933,028

57,933,028

57,933,028

57,933,028

0

24.20%

0

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

57,933,028

24.20%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

N/A

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will acquire:

0

12. Date on which proxy holder will acquire voting rights:

N/A

13. Additional information:

14. Contact name:

Peter Speirs, Company Secretary of Hikma Pharmaceuticals PLC

15. Contact telephone number:

[phone]

 

END

 

 

HOLUKRSRNRAUUAR